Pharmaceutical-Technology.com

Pharmaceutical-technology.com is part of a network of over 30 specialized B2B websites, reaching a vast global audience of active decision-makers, influencers, and thought leaders. Together, these platforms attract 55 million industry professionals each year. Being a part of GlobalData, we have access to an extensive database with over 1 billion data points that cover companies, deals, projects, forecasts, and trends. This wealth of information fuels our top-tier content. Our expertise spans more than 80 global markets and is supported by a dedicated team of over 800 award-winning journalists, researchers, and analysts, providing you with essential insights that can influence business outcomes. Our unique marketing solution combines award-winning targeting technology with our network of websites, offering a comprehensive approach that integrates insight, creativity, and advanced AI technology. This allows our clients to effectively identify, target, and engage with potential customers through access to our 30+ B2B media sites and their extensive sector-specific audiences. With unmatched reach, targeted data, and first-party data capabilities, we create outstanding campaigns for our clients. To learn more about our technology-driven marketing solution, please visit https://www.verdictmediastrategies.com/.

International, Trade/B2B

English

Magazine

Outlet metrics

Domain Authority

Ranking

Global

#231255

United States

#146838

Health/Pharmacy

#295

Traffic sources

Monthly visitors

Articles

Introducing AI into the pharma supply chain is a journey

2 days ago | pharmaceutical-technology.com | Fi Forrest

AI is revolutionizing the pharma supply chain by automating manual tasks, monitoring risks and providing predictive insights. While AI can help streamline processes, enhance procurement efficiency and shows potential to help improve patient safety, a human should always be in control says Sharp’s Dermot Somers and John Hoey. The proliferation of Artificial Intelligence (AI) in our lives has set about a true revolution in how we collect, organize and use data.
Ascletis daily acne tablet set for China review after Phase III win

3 days ago | pharmaceutical-technology.com | Robert Barrie

The Phase III trial, conducted by Chinese license partner Ascletis, produced strong results for denifanstat compared to potential rivals. Over 50 million people in the US live with acne. Maxbelchenko via Shutterstock. Sagimet Bioscience’s denifanstat, a one-daily pill for the treatment of acne, has succeeded in a Phase III trial, with the biotech’s license partner Ascletis Bioscience set to submit the drug for regulatory review in China.
Magazine: Are regulators keeping pace with AI adoption in clinical trials? - Pharmaceutical Technology

3 days ago | pharmaceutical-technology.com | Ross Law

As part of GlobalData's extensive network of websites, this site is dedicated to protecting your privacy. We may store and access personal data such as cookies, device identifiers or other similar technologies on your device and process such data to enhance site navigation, personalize ads and content when you visit our sites, measure ad and content performance, gain audience insights, analyze our site traffic as well as develop and improve our products and services.
Roche extends SMA market lead with Evrysdi tablet approval in Europe

3 days ago | pharmaceutical-technology.com | Robert Barrie

Already offering the only non-invasive treatment for SMA in liquid form, Roche’s Evrysdi now comes as a tablet. Evrysdi will remain available as a liquid formulation, which originally approved in Europe in 2021. ricochet64 via Shutterstock. Roche has won approval in Europe for a tablet formulation of its spinal muscular atrophy (SMA) treatment Evrysdi (risdiplam), as the drugmaker looks to extend its growing dominance in the neuromuscular disorder market.
ASCO25: AbbVie flexes ADC Phase I data as NSCLC market opportunity beckons

4 days ago | pharmaceutical-technology.com | Robert Barrie

AbbVie’s telisotuzumab dizutecan achieved an ORR of 63% in EGFR-mutant NSCLC patients, with current ADC options in this population lacking. According to a GlobalData report, the global NSCLC market, valued at $30.7bn in 2021, is set to grow to $45.4bn by 2031. Valeriya Zankovych via Shutterstock.
ASCO25: Genmab’s Rina-S en route to ‘blockbuster potential’ amid more positive data

4 days ago | pharmaceutical-technology.com | Robert Barrie

Clinical data for Genmab’s ADC Rina-S is mounting, as the pharma company plans more late-stage trials. Rina-S achieved a 50% confirmed objective response rate (ORR) as a monotherapy. Helena Nechaeva via Shutterstock. Genmab’s antibody drug conjugate (ADC) rinatabart sesutecan (Rina-S) demonstrated positive efficacy in treating patients with endometrial cancer, as investor confidence grows towards the drug’s blockbuster future.
BMS outlays $11bn to join BioNTech’s development of bispecific cancer drug

5 days ago | pharmaceutical-technology.com | Robert Barrie

BMS and BioNTech will jointly develop and commercialise the asset that targets both PD-L1 and VEGF-A. BMS and BioNTech are now contestants in a fast-moving clinical arena that looks to go beyond traditional single-mechanism checkpoint inhibitors. HJBC via Shutterstock. Bristol Myers Squibb (BMS) is joining forces with BioNTech in a deal that could surpass $11bn as the two drugmakers look to take on the dominance of MSD’s Keytruda (pembrolizumab) in solid tumour treatment.
ASCO25: MSD’s KRAS G12C drug shows early promise in Phase I

5 days ago | pharmaceutical-technology.com | Abigail Beaney

MSD is also investigating the KRAS G12C inhibitor in two Phase III trials. MSD investigated the KRAS G12C inhibitor in patients with solid tumours, including advanced colorectal cancer and non-small cell lung cancer. Image credit: Shutterstock / Atmosphere1. MSD’s investigational KRAS G12C inhibitor has shown signs of anti-tumour activity when used both alone and in combination with other oncology drugs.
ASCO25: Regeneron unpacks positive Libtayo data in adjuvant CSCC as Keytruda stumbles

5 days ago | pharmaceutical-technology.com | Robert Barrie

Additional data presented at ASCO highlights Libtayo’s ability to hold off recurrence of a type of skin cancer. CSCC is the second most common type of skin cancer and has a high rate of recurrence. Pixel-Shot via Shutterstock. Regeneron has fleshed out additional positive data for blockbuster immunotherapy Libtayo (cemiplimab) as an adjuvant therapy in high-risk cutaneous squamous cell carcinoma (CSCC), as rival PD-1 inhibitor Keytruda falters in the same indication.
ASCO25: MSD’s ADC candidate achieves 56.3% ORR in lymphoma trial

1 week ago | pharmaceutical-technology.com | Robert Barrie

MSD confirmed a recommended dose has been identified as the Phase III portion continues enrolment. ADC Therapeutics’ Zynlonta (loncastuximab tesirine-lpyl) is the only FDA-approved ADC for diffuse large B-cell lymphoma. Nemes Laszlo via Shutterstock.